Clinical Use of FSH in Male Infertility

Hermann M Behre, Hermann M Behre

Abstract

The established clinical indication for FSH use in male infertility is the treatment of patients with hypogonadotropic hypogonadism for stimulation of spermatogenesis that allows the induction of a clinical pregnancy in the female partner and finally the birth of a healthy child. Several clinical studies with urinary, purified, and recombinant FSH preparations in combination with hCG have demonstrated the high treatment efficacy regarding these clinical endpoints. Shortcomings of this hormone therapy are the long duration of treatment, sometimes longer than 2 years, and the inconvenience of injections every second or third day. However, improvements of therapy might be expected with new hormonal treatment options already available for infertility treatment in the female. FSH use for treatment of patients with normogonadotropic idiopathic infertility and oligozoospermia is still considered experimental in most countries. Recent meta-analyses have shown that FSH can significantly increase pregnancy rates in the female partners of these patients, but the effect-size is relatively low. Therefore, predictive factors for treatment success have to be identified, including FSH pharmacogenetics, to select the right normogonadotropic patients with idiopathic infertility for FSH therapy.

Keywords: idiopathic male infertility; FSH; hCG; hMG; hypogonadotropic hypogonadism; male infertiltiy.

References

    1. Oduwole OO, Peltoketo H, Huhtaniemi IT. Role of follicle-stimulating hormone in spermatogenesis. Front Endocrinol. (2018) 9:763. 10.3389/fendo.2018.00763
    1. Barbonetti A, Calogero AE, Balercia G, Garolla A, Krausz C, La Vignera S, et al. . The use of follicle stimulating hormone (FSH) for the treatment of the infertile man: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS). J Endocrinol Invest. (2018) 41:1107–22. 10.1007/s40618-018-0843-y
    1. Colpi GM, Francavilla S, Haidl G, Link K, Behre HM, Goulis DG, et al. . European academy of andrology guideline management of oligo-astheno-teratozoospermia. Andrology. (2018) 6:513–24. 10.1111/andr.12502
    1. Behre HM, Nieschlag E, Partsch C-J, Wieacker P, Simoni M. Diseases of the hypothalamus and the pituitary gland. In: Nieschlag E, Behre HM, Nieschlag S. editors. Andrology. Male Reproductive Health and Dysfunction. 3rd ed Berlin: Springer; (2010). p. 169–92.
    1. Nieschlag E, Behre HM. Testosterone therapy. In: Nieschlag E, Behre HM, Nieschlag S. editors. Andrology. Male Reproductive Health and Dysfunction. 3rd ed Berlin: Springer; (2010). p. 437–55.
    1. Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, et al. . LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. PLoS ONE. (2012) 7:e46682. 10.1371/journal.pone.0046682
    1. Young J, Xu C, Papadakis GE, Acierno JS, Maione L, Hietamaki J, et al. . Clinical management of congenital hypogonadotropic hypogonadism. Endocr Rev. (2019) 40:669–710. 10.1210/er.2018-00116
    1. Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol. (1998) 139:298–303. 10.1530/eje.0.1390298
    1. Mao JF, Liu ZX, Nie M, Wang X, Xu HL, Huang BK, et al. . Pulsatile gonadotropin-releasing hormone therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism. Asian J Androl. (2017) 19:680–5. 10.4103/1008-682X.193568
    1. Macleod J, Pazianos A, Ray BS. Restoration of human spermatogenesis by menopausal gonadotrophins. Lancet. (1964) 1:1196–7. 10.1016/S0140-6736(64)91212-7
    1. MacLeod J, Pazianos A, Ray B. The restoration of human spermatogenesis and of the reproductive tract with urinary gonadotropins following hypophysectomy. Fertil Steril. (1966) 17:7–23. 10.1016/S0015-0282(16)35821-6
    1. Kliesch S, Behre HM, Nieschlag E. Recombinant human follicle-stimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male. Fertil Steril. (1995) 63:1326–8. 10.1016/S0015-0282(16)57619-5
    1. Bouloux PM, Nieschlag E, Burger HG, Skakkebaek NE, Wu FC, Handelsman DJ, et al. . Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. J Androl. (2003) 24:604–11. 10.1002/j.1939-4640.2003.tb02712.x
    1. Blumenauer V, Czeromin U, Fehr D, Fiedler K, Gnoth C, Krüssel JS, et al. D·I·R annual 2017 – the German IVF-registry. J Reproduktionsmed Endrokrinol. (2018) 15:217–50.
    1. Rohayem J, Sinthofen N, Nieschlag E, Kliesch S, Zitzmann M. Causes of hypogonadotropic hypogonadism predict response to gonadotropin substitution in adults. Andrology. (2016) 4:87–94. 10.1111/andr.12128
    1. Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab. (1988) 66:1144–51. 10.1210/jcem-66-6-1144
    1. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, et al. . Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol. (2005) 173:2072–5. 10.1097/01.ju.0000158133.09197.f4
    1. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab. (2009) 94:801–8. 10.1210/jc.2008-1648
    1. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril. (2009) 92:594–604. 10.1016/j.fertnstert.2008.07.1720
    1. Dwyer AA, Raivio T, Pitteloud N. Gonadotrophin replacement for induction of fertility in hypogonadal men. Best Pract Res Clin Endocrinol Metab. (2015) 29:91–103. 10.1016/j.beem.2014.10.005
    1. Liu Z, Mao J, Wu X, Xu H, Wang X, Huang B, et al. . Efficacy and outcome predictors of gonadotropin treatment for male congenital hypogonadotropic hypogonadism: a retrospective study of 223 patients. Medicine. (2016) 95:e2867. 10.1097/MD.0000000000002867
    1. Anonymous Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotropin for treating men with isolated hypogonadotropic hypogonadism. European Metrodin HP Study Group. Fertil Steril. (1998) 70:256–62. 10.1016/S0015-0282(98)00156-3
    1. Bouloux P, Warne DW, Loumaye E, FSH Study Group in Men's Infertility . Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertil Steril. (2002) 77:270–3. 10.1016/S0015-0282(01)02973-9
    1. Sinisi AA, Esposito D, Bellastella G, Maione L, Palumbo V, Gandini L, et al. . Efficacy of recombinant human follicle stimulating hormone at low doses in inducing spermatogenesis and fertility in hypogonadotropic hypogonadism. J Endocrinol Invest. (2010) 33:618–23. 10.1007/BF03346659
    1. Nieschlag E, Bouloux PG, Stegmann BJ, Shankar RR, Guan Y, Tzontcheva A, et al. . An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reprod Biol Endocrinol. (2017) 15:17. 10.1186/s12958-017-0232-y
    1. Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics. (2013) 68 (Suppl 1):81–8. 10.6061/clinics/2013(Sup01)09
    1. Yang L, Zhang SX, Dong Q, Xiong ZB, Li X. Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience. Int Urol Nephrol. (2012) 44:393–9. 10.1007/s11255-011-0065-0
    1. Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol. (2002) 147:617–24. 10.1530/eje.0.1470617
    1. Zhang M, Tong G, Liu Y, Mu Y, Weng J, Xue Y, et al. . Sequential versus continual purified urinary FSH/hCG in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. (2015) 100:2449–55. 10.1210/jc.2014-3802
    1. Casarini L, Santi D, Brigante G, Simoni M. Two hormones for one receptor: evolution, biochemistry, actions, and pathophysiology of LH and hCG. Endocr Rev. (2018) 39:549–92. 10.1210/er.2018-00065
    1. Schill WB, Jungst D, Unterburger P, Braun S. Combined hMG/hCG treatment in subfertile men with idiopathic normogonadotrophic oligozoospermia. Int J Androl. (1982) 5:467–77. 10.1111/j.1365-2605.1982.tb00278.x
    1. Knuth UA, Honigl W, Bals-Pratsch M, Schleicher G, Nieschlag E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. J Clin Endocrinol Metab. (1987) 65:1081–7. 10.1210/jcem-65-6-1081
    1. Kamischke A, Behre HM, Bergmann M, Simoni M, Schafer T, Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod. (1998) 13:596–603. 10.1093/humrep/13.3.596
    1. Simoni M, Santi D, Negri L, Hoffmann I, Muratori M, Baldi E, et al. . Treatment with human, recombinant FSH improves sperm DNA fragmentation in idiopathic infertile men depending on the FSH receptor polymorphism p.N680S: a pharmacogenetic study. Hum Reprod. (2016) 31:1960–9. 10.1093/humrep/dew167
    1. Casamonti E, Vinci S, Serra E, Fino MG, Brilli S, Lotti F, et al. . Short-term FSH treatment and sperm maturation: a prospective study in idiopathic infertile men. Andrology. (2017) 5:414–22. 10.1111/andr.12333
    1. Muratori M, Baldi E. Effects of FSH on sperm DNA fragmentation: review of clinical studies and possible mechanisms of action. Front Endocrinol. (2018) 9:734. 10.3389/fendo.2018.00734
    1. Santi D, Spaggiari G, Simoni M. Sperm DNA fragmentation index as a promising predictive tool for male infertility diagnosis and treatment management - meta-analyses. Reprod Biomed Online. (2018) 37:315–26. 10.1016/j.rbmo.2018.06.023
    1. WHO WHO Laboratory Manual for the Examination and Processing of Human Semen. Geneva: WHO Press; (2010).
    1. Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev. (2013) CD005071 10.1002/14651858.CD005071.pub4
    1. Santi D, Granata AR, Simoni M. FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis. Endocr Connect. (2015) 4:R46–58. 10.1530/EC-15-0050
    1. Ding YM, Zhang XJ, Li JP, Chen SS, Zhang RT, Tan WL, et al. . Treatment of idiopathic oligozoospermia with recombinant human follicle-stimulating hormone: a prospective, randomized, double-blind, placebo-controlled clinical study in Chinese population. Clin Endocrinol. (2015) 83:866–71. 10.1111/cen.12770
    1. Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwasser P, et al. . Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics. (2005) 15:451–6. 10.1097/01.fpc.0000167330.92786.5e
    1. Ferlin A, Vinanzi C, Selice R, Garolla A, Frigo AC, Foresta C. Toward a pharmacogenetic approach to male infertility: polymorphism of follicle-stimulating hormone beta-subunit promoter. Fertil Steril. (2011) 96:1344–1349.e1342. 10.1016/j.fertnstert.2011.09.034
    1. Selice R, Ferlin A, Garolla A, Caretta N, Foresta C. Effects of endogenous FSH on normal human spermatogenesis in adults. Int J Androl. (2011) 34(6 Pt 2):e511–7. 10.1111/j.1365-2605.2010.01134.x
    1. Schubert M, Pérez Lanuza L, Gromoll J. Pharmacogenetics of FSH action in the male. Front Endocrinol. (2019) 10:47. 10.3389/fendo.2019.00047
    1. Barbotin AL, Ballot C, Sigala J, Leroy M, Rigot JM, Dewailly D, et al. . Pregnancy after intracytoplasmic sperm injection following extended sperm preparation and hormone therapy in an azoospermic man with maturation arrest and microlithiasis: a case report and literature review. Andrologia. (2017) 49:e12665. 10.1111/and.12665
    1. Cocci A, Cito G, Russo GI, Falcone M, Capece M, Timpano M, et al. . Effectiveness of highly purified urofollitropin treatment in patients with idiopathic azoospermia before testicular sperm extraction. Urologia. (2018) 85:19–21. 10.5301/uj.5000253
    1. Laursen RJ, Elbaek HO, Povlsen BB, Lykkegaard J, Jensen KBS, Esteves SC, et al. . Hormonal stimulation of spermatogenesis: a new way to treat the infertile male with non-obstructive azoospermia? Int Urol Nephrol. (2019) 51:453–6. 10.1007/s11255-019-02091-8
    1. Bundesärztekammer Richtlinie zur Entnahme und Übertragung von menschlichen Keimzellen im Rahmen der assistierten Reproduktion. Deutsches Ärzteblatt. (2018) A1–A22. 10.3238/arztebl.2018.Rili_assReproduktion_2018

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit